Amantadine Revisited: A Contender for Initial Treatment in Parkinson’s Disease?

Marmol, Sarah; Feldman, Matthew; Singer, Carlos; Margolesky, Jason

doi:10.1007/s40263-021-00862-5

Cited by 11 publications

(8 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Levodopa-related dyskinesia is typically treated with amantadine as an add-on medication, although more recently, novel long-acting amantadine formulations have been created with additional indications to treat motor fluctuations. Amantadine is hardly associated with impulse control problems and has not been found to produce dyskinesia [ 33 ]. Levodopa or anticholinergic medicine may occasionally be used with amantadine.…”

Section: Parkinson’s Disease: Backgroundmentioning

confidence: 99%

Imperative Role of Machine Learning Algorithm for Detection of Parkinson’s Disease: Review, Challenges and Recommendations

et al. 2022

View full text Add to dashboard Cite

Parkinson’s disease (PD) is a neurodegenerative disease that affects the neural, behavioral, and physiological systems of the brain. This disease is also known as tremor. The common symptoms of this disease are a slowness of movement known as ‘bradykinesia’, loss of automatic movements, speech/writing changes, and difficulty with walking at early stages. To solve these issues and to enhance the diagnostic process of PD, machine learning (ML) algorithms have been implemented for the categorization of subjective disease and healthy controls (HC) with comparable medical appearances. To provide a far-reaching outline of data modalities and artificial intelligence techniques that have been utilized in the analysis and diagnosis of PD, we conducted a literature analysis of research papers published up until 2022. A total of 112 research papers were included in this study, with an examination of their targets, data sources and different types of datasets, ML algorithms, and associated outcomes. The results showed that ML approaches and new biomarkers have a lot of promise for being used in clinical decision-making, resulting in a more systematic and informed diagnosis of PD. In this study, some major challenges were addressed along with a future recommendation.

show abstract

Section: Parkinson’s Disease: Backgroundmentioning

confidence: 99%

Imperative Role of Machine Learning Algorithm for Detection of Parkinson’s Disease: Review, Challenges and Recommendations

et al. 2022

View full text Add to dashboard Cite

show abstract

“… 357 Amantadine could reduce dyskinesia (involuntary movements) in PD patients receiving Levodopa. 358 Amantadine is an antiviral medicine with antiparkinsonian effects. Synergistic effects are observed when used in combination with Levodopa.…”

Section: Therapeutic Developmentmentioning

confidence: 99%

G protein-coupled receptors in neurodegenerative diseases and psychiatric disorders

Wong

et al. 2023

Sig Transduct Target Ther

View full text Add to dashboard Cite

Neuropsychiatric disorders are multifactorial disorders with diverse aetiological factors. Identifying treatment targets is challenging because the diseases are resulting from heterogeneous biological, genetic, and environmental factors. Nevertheless, the increasing understanding of G protein-coupled receptor (GPCR) opens a new possibility in drug discovery. Harnessing our knowledge of molecular mechanisms and structural information of GPCRs will be advantageous for developing effective drugs. This review provides an overview of the role of GPCRs in various neurodegenerative and psychiatric diseases. Besides, we highlight the emerging opportunities of novel GPCR targets and address recent progress in GPCR drug development.

show abstract

“…Another dopaminergic agonist, Amantadine was found to be promising in several brain injuries. It triggers the dopamine release in neurons and delays the reuptake of dopamine by neural cells and also inhibits the NMDA receptor signaling, thus proving its potential effect in the brain injuries [ 107 , 108 , 109 , 110 ]. A non-psychotropic cannabinoid (Dexanabinol), which acted as a potent NMDA receptor antagonist was also reported to have a potential effect in glutamate injury, but also showed unwanted side effects that impaired normal brain functioning [ 37 , 111 ].…”

Section: Mechanism Of Abimentioning

confidence: 99%

Understanding Acquired Brain Injury: A Review

et al. 2022

View full text Add to dashboard Cite

Any type of brain injury that transpires post-birth is referred to as Acquired Brain Injury (ABI). In general, ABI does not result from congenital disorders, degenerative diseases, or by brain trauma at birth. Although the human brain is protected from the external world by layers of tissues and bone, floating in nutrient-rich cerebrospinal fluid (CSF); it remains susceptible to harm and impairment. Brain damage resulting from ABI leads to changes in the normal neuronal tissue activity and/or structure in one or multiple areas of the brain, which can often affect normal brain functions. Impairment sustained from an ABI can last anywhere from days to a lifetime depending on the severity of the injury; however, many patients face trouble integrating themselves back into the community due to possible psychological and physiological outcomes. In this review, we discuss ABI pathologies, their types, and cellular mechanisms and summarize the therapeutic approaches for a better understanding of the subject and to create awareness among the public.

show abstract

Amantadine Revisited: A Contender for Initial Treatment in Parkinson’s Disease?

Cited by 11 publications

References 51 publications

Imperative Role of Machine Learning Algorithm for Detection of Parkinson’s Disease: Review, Challenges and Recommendations

Imperative Role of Machine Learning Algorithm for Detection of Parkinson’s Disease: Review, Challenges and Recommendations

G protein-coupled receptors in neurodegenerative diseases and psychiatric disorders

Understanding Acquired Brain Injury: A Review

Contact Info

Product

Resources

About